These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33547412)

  • 21. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.
    Greally M; Chou JF; Chatila WK; Margolis M; Capanu M; Hechtman JF; Tuvy Y; Kundra R; Daian F; Ladanyi M; Kelsen DP; Ilson DH; Berger MF; Tang LH; Solit DB; Diaz LA; Schultz N; Janjigian YY; Ku GY
    Clin Cancer Res; 2019 Oct; 25(20):6160-6169. PubMed ID: 31337644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.
    Ishikawa E; Nakamura M; Shimada K; Tanaka T; Satou A; Kohno K; Sakakibara A; Furukawa K; Yamamura T; Miyahara R; Nakamura S; Kato S; Fujishiro M
    J Gastroenterol; 2020 Jan; 55(1):39-50. PubMed ID: 31493237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia.
    Bösch F; Brüwer K; Altendorf-Hofmann A; Auernhammer CJ; Spitzweg C; Westphalen CB; Boeck S; Schubert-Fritschle G; Werner J; Heinemann V; Kirchner T; Angele M; Knösel T
    Endocr Relat Cancer; 2019 Mar; 26(3):293-301. PubMed ID: 30608901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
    Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab.
    Lee CK; Kim SS; Park S; Kim C; Heo SJ; Lim JS; Kim H; Kim HS; Rha SY; Chung HC; Park S; Jung M
    Oncotarget; 2017 May; 8(19):31169-31179. PubMed ID: 28415714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
    Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit.
    Jiang Y; Xie J; Han Z; Liu W; Xi S; Huang L; Huang W; Lin T; Zhao L; Hu Y; Yu J; Zhang Q; Li T; Cai S; Li G
    Clin Cancer Res; 2018 Nov; 24(22):5574-5584. PubMed ID: 30042208
    [No Abstract]   [Full Text] [Related]  

  • 29. Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy.
    Baglivo S; Bianconi F; Metro G; Gili A; Tofanetti FR; Bellezza G; Ricciuti B; Mandarano M; Teti V; Siggillino A; Reda MS; Chiari R; Pistola L; Sidoni A; Minotti V; Roila F; Ludovini V
    Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34209514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review.
    Spagnolo F; Boutros A; Cecchi F; Croce E; Tanda ET; Queirolo P
    BMC Cancer; 2021 Apr; 21(1):425. PubMed ID: 33865350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer.
    Yagi T; Baba Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Baba H
    Ann Surg; 2019 Mar; 269(3):471-478. PubMed ID: 29206673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of neoadjuvant chemotherapy on lymphocytes and co-inhibitory B7-H4 molecule in gastric cancer: low B7-H4 expression associates with favorable prognosis.
    Maskey N; Li K; Hu M; Xu Z; Peng C; Yu F; Cao H; Chen J; Li Y; Yang G
    Tumour Biol; 2014 Dec; 35(12):11837-43. PubMed ID: 25260881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome.
    Bekos C; Pils D; Dekan S; Hofstetter G; Horak P; Reinthaller A; Polterauer S; Schwameis R; Aust S
    Sci Rep; 2021 Mar; 11(1):6400. PubMed ID: 33737722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
    Snyder A; Nathanson T; Funt SA; Ahuja A; Buros Novik J; Hellmann MD; Chang E; Aksoy BA; Al-Ahmadie H; Yusko E; Vignali M; Benzeno S; Boyd M; Moran M; Iyer G; Robins HS; Mardis ER; Merghoub T; Hammerbacher J; Rosenberg JE; Bajorin DF
    PLoS Med; 2017 May; 14(5):e1002309. PubMed ID: 28552987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
    Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer.
    Yin H; Guo W; Sun X; Li R; Feng C; Tan Y
    J Immunol Res; 2020; 2020():8345235. PubMed ID: 32964058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
    Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
    AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
    D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
    Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.